PRME (Prime Medicine, Inc.) Stock Financials & Earnings | Market Cap Arena

PRME (Prime Medicine, Inc.) Stock Financials & Earnings | Market Cap Arena

PRMEPrime Medicine, Inc.

Mkt Cap$771M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$5M

Net Income (TTM)-$201M

EPS (TTM)-$1.35

Free Cash Flow (TTM)-$167M

Gross Margin0.0%

Op. Margin-4498.1%

Net Margin-4342.4%

FCF Margin-3607.4%

P/S Ratio (TTM)166.4x

P/E Ratio (TTM)—

YoY Rev Growth+55.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$40M
Q2 23	$0	$0	-$45M
Q3 23	$0	$0	-$51M
Q4 23	$0	$0	-$68M
Q1 24	$591K	-$724K	-$48M
Q2 24	$0	$0	-$56M
Q3 24	$209K	$209K	-$54M
Q4 24	$2M	$2M	-$44M
Q1 25	$1M	$1M	-$52M
Q2 25	$1M	-$749K	-$53M
Q3 25	$1M	-$43M	-$54M
Q4 25	$838K	$42M	-$49M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	1304.2x	—
Q2 24	1304.2x	—
Q3 24	963.5x	—
Q4 24	258.4x	—
Q1 25	200.4x	—
Q2 25	155.4x	—
Q3 25	129.0x	—
Q4 25	166.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$42M	-$44M
Q2 23	-$41M	-$43M
Q3 23	-$39M	-$42M
Q4 23	-$44M	-$46M
Q1 24	-$68M	-$70M
Q2 24	-$45M	-$47M
Q3 24	-$26M	-$27M
Q4 24	$16M	$14M
Q1 25	-$49M	-$51M
Q2 25	-$41M	-$43M
Q3 25	-$35M	-$35M
Q4 25	-$37M	-$38M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$2M
Q3 23	$3M
Q4 23	$2M
Q1 24	$2M
Q2 24	$2M
Q3 24	$1M
Q4 24	$2M
Q1 25	$2M
Q2 25	$2M
Q3 25	$247K
Q4 25	$290K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+101.2%
Q2 23	—	+72.0%
Q3 23	—	+62.6%
Q4 23	—	+75.9%
Q1 24	—	+22.2%
Q2 24	—	+23.0%
Q3 24	—	+5.8%
Q4 24	—	-31.8%
Q1 25	+146.0%	+10.0%
Q2 25	—	-2.1%
Q3 25	+486.1%	+1.4%
Q4 25	-61.6%	+6.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$5M	881.4%
Q2 24	$0	—
Q3 24	$7M	3266.5%
Q4 24	$6M	272.1%
Q1 25	$6M	390.7%
Q2 25	$6M	567.3%
Q3 25	$13M	1040.6%
Q4 25	$5M	538.8%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$31M	$9M
Q2 23	$35M	$11M
Q3 23	$41M	$10M
Q4 23	$41M	$13M
Q1 24	$38M	$11M
Q2 24	$43M	$13M
Q3 24	$40M	$14M
Q4 24	$34M	$12M
Q1 25	$41M	$13M
Q2 25	$41M	$13M
Q3 25	$44M	$11M
Q4 25	$35M	$15M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$1M
Q2 25	$1M
Q3 25	$1M
Q4 25	$838K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$133M	$116M	$250M
Q2 23	$121M	$87M	$208M
Q3 23	$44M	$121M	$165M
Q4 23	$42M	$80M	$122M
Q1 24	$94M	$117M	$211M
Q2 24	$56M	$107M	$163M
Q3 24	$118M	$58M	$176M
Q4 24	$182M	$8M	$190M
Q1 25	$92M	$52M	$144M
Q2 25	$54M	$48M	$102M
Q3 25	$71M	$137M	$208M
Q4 25	$63M	$115M	$178M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	89M	-8.4%
Q2 23	90M	+1.6%
Q3 23	92M	+1.5%
Q4 23	97M	+6.0%
Q1 24	104M	+7.3%
Q2 24	119M	+14.1%
Q3 24	120M	+0.5%
Q4 24	119M	-1.0%
Q1 25	131M	+10.4%
Q2 25	129M	-1.3%
Q3 25	161M	+24.2%
Q4 25	149M	-7.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	—	—
FY 22	$0	175
FY 23	$0	234
FY 24	$14K	214
FY 25	$46	100K